This Infographic activity uses a self-directed, graphic approach to introducing emerging hemophilia A and hemophilia B therapies. In this activity, Steven Pipe, MD and Guy Young, MD introduce the unmet medical needs experienced by patients with hemophilia. They review the mechanisms of action and most recent clinical trial data for the most advanced substitution therapies (emicizumab), hemostatic rebalancing agents (concizumab, marstacimab, and fitusiran), and gene therapies. The faculty also discuss how approval of these treatments could affect patient care, and the questions that need to be addressed in ongoing phase 3 clinical trials for them to enter clinical practice.
Course Credit:
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
Dates:
Opens: 2022-07-29
Closes: 2023-07-29
Target Audience:
This activity was developed for pediatric and adult hematologists and nurse practitioners who specialize in treating patients with hemophilia, especially those practicing in hemophilia treatment centers (HTCs) or who treat complex cases (eg, patients with inhibitors).
This activity is supported by an independent medical education grant from Novo Nordisk, Inc.
-
Steven Pipe, MD
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan -
Guy Young, MD
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California
